{"url_path":"/sec/prok/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1850270/0001193125-26-225841-index.html","accession_number":"0001193125-26-225841","cik":"0001850270","ticker":"PROK","issuer_name":"PROKIDNEY CORP.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1850270/0001193125-26-225841-index.html","primary_entity_key":"0001850270","primary_entity_name":"PROKIDNEY CORP."},"word_count":54,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nDuring the quarter ended March 31, 2026, none of the Company’s directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."}